Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
This grant opportunity focuses on supporting early-stage clinical trials for new treatments targeting Alzheimer's disease and related dementias. It combines initial phase 1 and early phase 1b/2a trials into one process. Eligible interventions should target mechanisms other than amyloid and tau proteins and aim to improve cognitive and/or neuropsychiatric symptoms across different stages of the…
Source
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
Get the full picture on this opportunity
Create a free Scout account to unlock everything you need to decide fast and win the grant.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Deep agency & funder detail
Program context, sub-agency structure, and a full eligibility breakdown.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Similar opportunities
Discover related funding matched to your work.
Already have an account? Sign In
Trusted by 500+ Happy Customers